Mirabegron Glenmark

Mirabegron, the active ingredient in Mirabegron Glenmark, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the treatment of overactive bladder symptoms—including urinary urgency, frequency, and urge incontinence—in adult patients and is marketed in the European Union.

GNH USA supplies Mirabegron Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide, ensuring consistent product quality, regulatory compliance and reliable logistics for global healthcare providers through established distribution networks.

Mirabegron acts on the β3‑adrenergic pathway to improve bladder storage function in patients with overactive bladder.

- Overactive bladder: reduces urinary urgency and frequency by increasing bladder capacity. - Urinary urgency: lessens the sudden, strong need to void. - Frequency: decreases the number of daytime voids. - Urge incontinence: helps prevent involuntary leakage associated with urgency.

Common Side Effects: - Hypertension: elevated blood pressure observed in some patients. - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Urinary tract infection: increased susceptibility to bacterial infection of the urinary system. - Headache: mild to moderate head pain. - Constipation: reduced bowel motility. - Dry mouth: decreased salivation.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder. - Severe hypertension: markedly high blood pressure requiring medical attention. - Tachycardia: rapid heart rate. - Angioedema: swelling of the face, lips, or throat. - Myocardial infarction: rare occurrence of heart attack. - Anaphylaxis: severe allergic reaction requiring immediate care.

Mirabegron should be used with caution in the following situations: - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: assess liver function before initiating treatment. - Hypertension: regularly check blood pressure during therapy. - Concomitant anticholinergics: evaluate for additive anticholinergic effects. - Pregnancy: safety not established; use only if potential benefit justifies risk. - Store at room temperature: keep in the original container, protect from moisture and light.

Mirabegron may interact with several drug classes. Review the following interactions before prescribing:

Major Interactions (Avoid): - Strong CYP2D6 inhibitors: may increase mirabegron plasma concentrations. - Norepinephrine reuptake inhibitors: heightened risk of hypertension. - Antihypertensive agents: potential reduction in blood pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - Diuretics: additive effect on blood pressure control. - Anticholinergics: possible reduction in therapeutic benefit for bladder symptoms. - Beta‑blockers: potential pharmacodynamic interaction affecting cardiovascular response.